Critical design features of phenyl carboxylate-containing polymer microbicides

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 3081-3089

  Rando, Robert F ^a   Obara, Sakae ^b   Osterling, Mark C ^c   Mankowski, Marie ^c   Miller, Shendra R ^d   Ferguson, Mary L ^d   Krebs, Fred C ^d   Wigdahl, Brian ^d   Labib, Mohamed ^a   Kokubo, Hiroyasu ^b  

^a Novaflux Biosciences Inc   (United States)

^b SHIN ETSU CHEMICAL CO LTD   (Japan)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; CELLACEFATE; CELLULOSE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE TRIMELLITATE; MICROBICIDE; PHENYL GROUP; POLYMER; SULFATE; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PKA; PRIORITY JOURNAL; VAGINA; VIRUS INFECTIVITY; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; BENZOIC ACID; CELLULOSE; DRUG DESIGN; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LEUKOCYTES, MONONUCLEAR; METHYLCELLULOSE; POLYMERS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP; TRICARBOXYLIC ACIDS;

EID: 33748681545     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01609-05     Document Type: Article

References (43)

1. Beer, B. E., G. F. Doncel, F. C. Krebs, R. J. Shattock, P. S. Fletcher, R. W. Buckheil, Jr., K. Watson, C. S. Dezzutti, J. E. Cummins, E. Bromley, N. Richardson-Harman, L. A. Pallansch, C. Lackman-Smith, C. Osterling, M. Mankowski, S. R. Miller, B. J. Catalone, P. A. Welsh, M. K. Howett, B. Wigdahl, J. A. Turpin, and P. Reichelderfer. 2006. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob. Agents Chemother. 50:1713-1723.
2. Boskey, E. R., K. M. Telsch, K. J. Whaley, T. R. Moench, and R. A. Cone. 1999. Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect. Immun. 67:5170-5175.
3. Brown, H. C., D. H. McDaniel, and O. Hafliger. 1955 Dissociation constants, p. 567-662. In E. A. Braude and F. C. Nachod (ed.), Determination of organic structures by physical methods. Academic Press Inc., New York, N.Y.
4. Buckheit, R. W., and R. Swanstrom. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retrovir. 7:295-302.
5. Catalone, B. J., T. M. Kish-Catalone, L. R. Dudgeon, E. B. Neely, M. Ferguson, F. C. Krebs, M. K. Howett, M. Labib, R. Rando, and B. Wigdahl. 2004. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob. Agents Chemother. 48:1837-1847.
6. Cheshenko, N., M. J. Keller, V. MasCasullo, G. A. Jarvis, H. Cheng, M. John, J.-H. Li, K. Hogarty, R. A. Anderson, D. P. Waller, L. J. D. Zaneveld, A. T. Profy, M. E. Klotman, and B. C. Herold. 2004. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents and Chemother. 48:2025-2036.
7. Coggins, C., K. Blanchard, F. Alvarez, V. Brache, E. Weisberg, P. H. Kilmarx, M. Lacarra, R. Massai, D. Mishell, Jr., A. Salvatierra, P. Witwatwongwana, C. Elias, and C. Ellertson. 2000. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 76:480-483.
8. de Muys, J.-M., H. Gourdeau, N. Nguyen-Ba, D. L. Taylor, P. S. Ahmed, T. Mansour, C. Locas, N. Richard, M. A. Wainberg, and R. F. Rando. 1999. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrob. Agents Chemother. 43:1835-1844.
9. Dezzutti, C. S., V. N. James, A. Ramos, S. T. Sullivan, A. Siddig, T. J. Bush, L. A. Grohskopf, L. Paxton, S. Subbarao, and C. E. Hart. 2004. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48:3834-3844.
10. Elias, C. J., C. Coggins, F. Alvarez, V. Brache, I. S. Fraser, M. Lacarra, P. Lahteenmaki, R. Massai, D. R. Mishell, Jr., D. M. Phillips, and A. M. Salvatierra. 1997. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception 56:387-389.
11. Esté, J. A., D. Schols, K. De Vreese, K. Van Laethem, A.-M. Vandamme, J. Desmyter, and E. De Clercq. 1997. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 52:98-104.
12. Esté, J. A, C. Cabrera, D. Schols, P. Cherepanov, A. Gutierrez, M. Witvrouw, C. Pannecouque, Z. Debyser, R. F. Rando, B. Clotet, J. Desmyter, and E. De Clercq. 1998. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. 53:340-345.
13. Greenhead, P., P. Hayes, P. S. Watts, K. G. Laing, G. E. Griffin, and R. J. Shattock. 2000. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J. Virol. 74:5577-5586.
14. Gu, Z., M. A. Wainberg, N. Nguyen-Ba, L. L'Heureux, J.-M. de Muys, T. L. Bowlin, and R. F. Rando. 1999. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 43:2376-2382.
15. Gyotoku, T., L. Aurelian, and A. R. Neurath. 1999. Cellulose acetate phthalate (CAP): an 'inactive' pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection. Antivir. Chem. Chemother. 10:327-332.
16. Herold, B. C., I. Scordi-Bello, N. Cheshenko, D. Marcellino, M. Dzuzelewski, F. Francois, R. Morin, V. Mas Casullo, R. A. Anderson, C. Chany II, D. P. Waller, L. J. D. Zaneveld, and M. E. Klotman. 2002. Mandelic acid condensation polymer: Novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. J. Virol. 76:11236-11244.
17. Hicks, D. R., L. S. Martin, J. P. Getchell, J. L. Heath, D. P. Francis, J. S. McDougal, J. W. Curran, and B. Voeller. 1985. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet 2:1422-1423.
18. Kokubo, H., S. Obara, K. Minemura, and T. Tanaka. 1997. Development of cellulose derivatives as novel enteric coatings agents soluble at pH 3.5-4.5 and higher. Chem. Pharm. Bull. 45:1350-1353.
19. Lappas, L. C., and W. McKeehan. 1967. Polymeric pharmaceutical coating materials. I. Preparation and properties. J. Pharm. Sci. 56:1257-1261.
20. Lide, D. R. (ed.) CRC handbook of chemistry and physics, 78th ed., 1997-1998. CRC Press LLC, Boca Raton, Fla.
21. Lynch, G., L. Low, S. Li, A. Sloane, S. Adams, C. Parish, B. Kemp, and A. L. Cunningham. 1994. Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection. J. Leukoc. Biol. 56:266-272.
22. Manson, K. H., M. S. Wyand, C. Miller, and A. R. Neurath. 2000. Effect of a dellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob. Agents Chemother. 44:3199-3202.
23. Mauck, C., D. H. Weiner, S. Ballagh, M. Creinin, D. F. Archer, J. Schwartz, H. Pymar, J. J. Lai, and M. Callahan. 2001. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase 1 safety and colposcopy study. Contraception 64:383-391.
24. Mörner, A., Å. Björndal, J. Albert, V. N. Kewalramani, D. R. Littman, R. Inoue, R. Thorstensson, E. M. Fenyö, and E. Björling. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:2343-2349.
25. Moulard, M., H. Lortat-Jacob, I. Mondor, G. Roca, R. Wyatt, J. Sodroski, L. Zhao, W. Olson, P. D. Kwong, and Q. J. Sattentau. 2000. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74:1948-1960.
26. Neurath, A. R. 2000. Microbicide for prevention of sexually transmitted diseases using a pharmaceutical excipient. AIDS Patient Care STDs. 14:215-219.
27. Neurath, A. R., Y.-Y. Li, R. Mandeville, and L. Richard. 2000. In vitro activity of a cellulose acetate phthalate topical cream against organisms associated with bacterial vaginosis. J. Antimicrob. Chemother. 45:713-714.
28. Neurath, A. R., N. Strick, S. Jiang, Y.-Y. Li, and A. K. Debnath. 2002. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect. Dis. 2:6.
29. Neurath, A. R., N. Strick, and Y.-Y. Li. 2002. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect. Dis. 2:27.
30. Neurath, A. R., N. Strick, Y.-Y. Li, and A. K. Debnath. 2001. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect. Dis. 1:17.
31. Neurath, A. R., N. Strick, Y.-Y. Li, K. Lin, and S. Jiang. 1999. Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. Biologicals 27:11-21.
32. Ojwang, J. O., R. W. Buckheit, Y. Pommier, A. Mazumder, K. De Vreese, J. A. Esté, D. Reymen, L. A. Pallansch, C. Lackman-Smith, T. L. Wallace, E. De Clercq, M. S. McGrath, and R. F. Rando. 1995. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:2426-2435.
33. Over, M., and P. Piot. 1996. Human immunodeficiency virus infection and other sexually transmitted diseases in developing countries: public health importance and priorities for resource allocation. J. Infect. Dis. 174(Suppl. 2):162-175.
34. Patton, D. L., Y. T. Cosgrove Sweeney, L. K. Rabe, and S. L. Hillier. 2002. Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex. Transm. Dis. 29:581-587.
35. Perine, P. L. 1994. Sexually transmitted diseases in the tropics. Med. J. Aust. 160:358-363, 366.
36. Piret, J., J. Lamontagne, J. Bestman-Smith, S. Roy, P. Gourde, A. Désormeaux, R. F. Omar, J. Juhász, and M. G. Bergeron. 2000. In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J. Clin. Microbiol. 38:110-119.
37. Richard, N., H. Salomon, R. Rando, T. Mansour, T. L. Bowlin, and M. A. Wainberg. 2000. Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy- 3′-oxa-4′-thio-5-fluorocytidine. Antimicrob. Agents Chemother. 44:1127-1131.
38. Rosenstein, I. J., M. K. Stafford, V. S. Kitchen, H. Ward, J. N. Weber, and D. Taylor-Robinson. 1998. Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J. Infect. Dis. 177:1386-1390.
39. Schols, D., R. Pauwels, J. Desmyter, and E. De Clercq. 1990. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 175:556-561.
40. Scordi-Bello, I. A., A. Mosoian, C. He, Y. Chen, Y. Cheng, G. A. Jarvis, M. J. Keller, K. Hogarty, D. P. Waller, A. T. Profy, B. C. Herold, and M. E. Klotman. 2005. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49:3607-3615.
41. St. Louis, M. E., W. C. Levine, J. N. Wasserheit, K. M. DeCock, G. R. West, D. R. Holtgrave, and R. O. Valdiserri. 1998. HIV prevention through early detection and treatment of other sexually transmitted diseases-United States recommendations of the Advisory Committee for HIV and STD Prevention. Morb. Mortal. Wkly. Rep. 47:1-24.
42. Taylor, D. L., P. S. Ahmed, A. S. Tyms, L. J. Wood, L. A. Kelly, P. Chambers, J. Clarke, J. Bedard, T. L. Bowlin, and R. F. Rando. 2000. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(±)-2′-deoxy-3′-oxa-4′- thiocytidine, dOTC]. Antivir. Chem. Chemother. 11:291-301.
43. Van Damme, L., A. Wright, K. Depraetere, I. Rosenstein, V. Vandersmissen, L. Poulter, M. McKinlay, E. Van Dyck, J. Weber, A. Profy, M. Laga, and V. Kitchen. 2000. A phase 1 study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Transm. Infect. 76:126-130.